SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).

被引：0
|
作者：
Hanauer, Stephen B.
Colombel, Jean Frederic
Sandborn, William J.
Sands, Bruce E.
Schreiber, Stefan
Danese, Silvio
Kierkus, Jaroslaw
Kulynych, Roman
Klopocka, Maria
Lahat, Adi
Gonciarz, Maciej
Osipenko, Marina
Borzan, Vladimir
Kowalski, Maciej
Saenko, Daria V.
Sardinov, Ruslan
Kim, Sung Hyun
Bae, Yunju
Lee, Sunhee
Yang, Siyoung
Lee, Juhyun
Lee, Sang Joon
Lee, Seul Gi
Park, Gahee
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1028
引用
收藏
页码：S220 / S221
页数：2
相关论文
共 50 条
  • [41] Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
    Panes, Julian
    Sandborn, William J.
    Schreiber, Stefan
    Sands, Bruce E.
    Vermeire, Severine
    D'Haens, Geert
    Panaccione, Remo
    Higgins, Peter D. R.
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Chan, Gary
    Moscariello, Michele
    Wang, Wenjin
    Niezychowski, Wojciech
    Marren, Amy
    Healey, Paul
    Maller, Eric
    GUT, 2017, 66 (06) : 1049 - 1059
  • [42] Infliximab for Prevention of Recurrence of Post-Surgical Crohn's Disease Following Ileocolonic Resection: A Randomized, Placebo-Controlled Study
    Regueiro, Miguel
    Feagan, Brian G.
    Zou, Bin
    Johanns, Jewel
    Blank, Marion
    Chevrier, Marc
    Plevy, Scott E.
    Popp, Jay
    Cornillie, Freddy
    Lukas, Milan
    Danese, Silvio
    Gionchetti, Paolo
    Molenda, Mark R.
    Hanauer, Stephen B.
    Reinisch, Walter
    Sandborn, William
    Sorrentino, Dario
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2015, 148 (04) : S141 - S141
  • [43] Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences
    Carbonnel, Franck
    Meyer, Antoine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (02) : 251 - 252
  • [44] Randomized placebo controlled trial of pro- and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn's disease (CD)
    Rutgeerts, P
    D'Haens, G
    Baert, F
    Van Assche, G
    Aerden, I
    Noman, M
    Vermeire, S
    Bengmark, S
    GASTROENTEROLOGY, 2004, 126 (04) : A467 - A467
  • [45] Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
    Lémann, M
    Mary, JY
    Duclos, B
    Veyrac, M
    Dupas, JL
    Delchier, JC
    Laharie, D
    Moreau, J
    Cadiot, G
    Picon, L
    Bourreille, A
    Sobahni, I
    Colombel, JF
    GASTROENTEROLOGY, 2006, 130 (04) : 1054 - 1061
  • [46] Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy for Crohn's Disease: Results From the Phase 3 Randomized, Double-Blind, Placebo-Controlled DIVERSITY1 Study
    Vermeire, Severine
    Rubin, David T.
    Watanabe, Mamoru
    Schreiber, Stefan
    Mehta, Rajiv
    Roblin, Xavier
    Genovese, Mark C.
    Masior, Tomasz
    Barron, Rahul
    Le Brun, Franck-Olivier
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S673 - S675
  • [47] Vedolizumab Maintenance Therapy for Crohn's Disease: Results of GEMINI II, a Randomized, Placebo-Controlled, Double-Blind, Multi-center Phase 3 Trial
    Hanauer, Stephen
    Colombel, Jean-Frederic
    Feagan, Brian
    Rutgeerts, Paul
    Sandborn, William
    Sands, Bruce
    Lukas, Milan
    Fedorak, Richard
    Lee, Scott
    Bressler, Brian
    Fox, Irving
    Xu, Jing
    Sankoh, Serap
    Stephens, Kristin
    Milch, Catherine
    Parikh, Asit
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S620 - S621
  • [48] Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
    Kim, Y. H.
    Ye, B. D.
    Pesegova, M.
    Alexeeva, O.
    Osipenko, M.
    Lahat, A.
    Dorofeyev, A.
    Salamon, A.
    Fishman, S.
    Levchenko, O.
    Cheon, J. H.
    Scribano, M. L.
    Mateescu, R. -B.
    Lee, K. M.
    Eun, C. S.
    Lee, S. J.
    Lee, S. Y.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S62 - S62
  • [49] A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease
    Sutherland, LR
    Martin, F
    Bailey, RJ
    Fedorak, RN
    Poleski, M
    Dallaire, C
    Rossman, R
    Saibil, F
    Lariviere, L
    Meyer, D
    Baker, SJ
    Alvi, AW
    Bass, S
    Blustein, PK
    Bridges, RJ
    Lay, TE
    vanRosendaal, GMA
    Watson, MH
    Clermont, R
    Cockeram, AW
    Mabey, M
    DaCosta, L
    Beck, IT
    Depew, W
    Groll, A
    Paterson, W
    Simon, J
    Vanner, S
    DAmore, D
    Sherbaniuk, R
    Cherry, R
    Lalor, E
    Thomson, ABR
    Yacyshyn, B
    Bain, V
    Fisher, D
    Kirdeikis, P
    Halle, P
    Irvine, EJ
    Collins, SM
    Croitoru, K
    Crowe, SE
    Goodacre, RL
    Hunt, RH
    Sabena, BJ
    Donnelly, M
    Khan, MAR
    Langevin, S
    Menard, DB
    Haddad, H
    GASTROENTEROLOGY, 1997, 112 (04) : 1069 - 1077
  • [50] Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center
    Farkas, Klaudia
    Rutka, Mariann
    Ferenci, Tamas
    Nagy, Ferenc
    Balint, Anita
    Bor, Renata
    Milassin, Agnes
    Fabian, Anna
    Szanto, Kata
    Vegh, Zsuzsanna
    Kurti, Zsuzsanna
    Lakatos, Peter L.
    Szepes, Zoltan
    Molnar, Tamas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (11) : 1325 - 1332
12345